A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
NCT06609005
This study is recruiting at 7 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase 1 and Phase 2 study to evaluate the safety and antitumor activity of INV-9956 in adult patients with advanced metastatic Castration Resistant Prostate Cancer.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Metastatic Castration Resistant Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
- Last updated on ClinicalTrials.gov
- June 4, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Honor Health · Scottsdale, AZ
California · 2
- Hoag Family Cancer Institute · Newport Beach, CA
- UC Irvine Medical Center · Orange, CA
Texas · 2
- Next Oncology - Houston · Houston, TX
- UT Health · San Antonio, TX
Virginia · 1
- NEXT Oncology · Fairfax, VA
Washington · 1
- Summit Cancer Centers · Spokane, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.